CompareMarketResearchRequest a sample
Home / Healthcare / Vaccines

Healthcare · Market report

Vaccines Market Size, Share and Forecast 2026-2036

The global vaccines market is worth USD 80.6 bn in 2026 and is forecast to reach USD 158 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Childhood combination and others is the largest by disease segment.

USD 80.6 bnMarket size 2026
USD 158 bnForecast 2036
7.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global vaccines market is worth USD 80.6 bn in 2026 and is forecast to reach USD 158 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Childhood combination and others is the largest by disease segment.

ScopeVaccines against infectious disease for humans, including childhood, adult, travel, influenza, pneumococcal, HPV, shingles, meningococcal, COVID-19 and RSV vaccines.
IndustryHealthcare
Value 2025USD 76.0 bn
Value 2026USD 80.6 bn
Value 2036USD 158 bn
CAGR 2026-20367.0%
Volume 20266,788 million doses
Volume 203611,506 million doses
Average price 2026USD 11.9 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Vaccines market size and forecast, 2026-2036

Exhibit 1The global vaccines market is forecast to grow from USD 80.6 bn in 2026 to USD 158 bn by 2036, a rise of 97%Global market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 7.0%
Vaccines market value, 2025 to 2036Market value by year. 2025: USD 76.0 bn; 2026: USD 80.6 bn; 2027: USD 86.2 bn; 2028: USD 92.2 bn; 2029: USD 98.7 bn; 2030: USD 106 bn; 2031: USD 113 bn; 2032: USD 121 bn; 2033: USD 129 bn; 2034: USD 138 bn; 2035: USD 148 bn; 2036: USD 158 bn. Compound annual growth rate 2026 to 2036: 7.0%.202580.6 bn2026113 bn2031158 bn20367.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 80.6 bn
2027USD 86.2 bn
2028USD 92.2 bn
2029USD 98.7 bn
2030USD 106 bn
2031USD 113 bn
2032USD 121 bn
2033USD 129 bn
2034USD 138 bn
2035USD 148 bn
2036USD 158 bn

Vaccines market segmentation

By disease

Exhibit 2Childhood combination and others is the largest segment by disease, with 33.0% of 2026 revenueEstimated share of 2026 global revenue, by disease
Vaccines market share by disease, 2026Share of 2026 revenue by disease. Childhood combination and others: 33.0%; Pneumococcal: 17.0%; HPV and shingles: 17.0%; Influenza: 11.0%; COVID-19: 8.0%; Meningococcal: 7.0%; RSV: 7.0%.Childhood combination and others33.0%Pneumococcal17.0%HPV and shingles17.0%Influenza11.0%COVID-198.0%Meningococcal7.0%RSV7.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Pneumococcal17.0%15.8%USD 13.7 bn6.2%
Influenza11.0%9.3%USD 8.9 bn5.2%
HPV and shingles17.0%17.4%USD 13.7 bn7.2%
COVID-198.0%5.3%USD 6.4 bn2.7%
Meningococcal7.0%6.8%USD 5.6 bn6.7%
RSV7.0%14.7%USD 5.6 bn15.2%
Childhood combination and others33.0%30.7%USD 26.6 bn6.2%

By technology

Exhibit 3Conjugate and subunit adds the most revenue by technology, growing from USD 41.9 bn in 2026 to USD 81.9 bn by 2036Estimated revenue in USD by technology, 2026 and 2036 forecast
Vaccines market by technology, 2026 and 2036Revenue by technology in 2026 and 2036. Conjugate and subunit: USD 41.9 bn in 2026, USD 81.9 bn in 2036, change +96%; mRNA and vector: USD 16.9 bn in 2026, USD 43.6 bn in 2036, change +158%; Live attenuated: USD 12.1 bn in 2026, USD 18.7 bn in 2036, change +54%; Inactivated: USD 9.7 bn in 2026, USD 14.2 bn in 2036, change +47%.20262036 forecastChangeConjugate and subunit+96%41.9 bn81.9 bnmRNA and vector+158%16.9 bn43.6 bnLive attenuated+54%12.1 bn18.7 bnInactivated+47%9.7 bn14.2 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Conjugate and subunit52.0%51.7%USD 41.9 bn6.9%
Live attenuated15.0%11.8%USD 12.1 bn4.4%
Inactivated12.0%9.0%USD 9.7 bn3.9%
mRNA and vector21.0%27.5%USD 16.9 bn9.9%

By age

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Paediatric36.0%30.0%USD 29.0 bn5.1%
Adult42.0%46.0%USD 33.8 bn8.0%
Elderly22.0%24.0%USD 17.7 bn7.9%

By administration

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Intramuscular62.0%60.0%USD 49.9 bn6.7%
Subcutaneous14.0%14.0%USD 11.3 bn7.0%
Oral and intranasal10.0%12.0%USD 8.1 bn9.0%
Intradermal and other14.0%14.0%USD 11.3 bn7.0%

By buyer

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Public programs46.0%44.0%USD 37.1 bn6.5%
Private market34.0%34.0%USD 27.4 bn7.0%
Travel and occupational20.0%22.0%USD 16.1 bn8.0%

Top 25 countries for vaccines by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 74.5% of 2026 revenue and the 25 countries below together hold 91.8%.

Exhibit 4United States is the largest country market at USD 29.0 bn in 2026, and the three largest countries hold 51.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Vaccines market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 29.0 bn, 36.0%; China: USD 8.1 bn, 10.0%; Germany: USD 4.0 bn, 5.0%; Japan: USD 4.0 bn, 5.0%; France: USD 3.2 bn, 4.0%; United Kingdom: USD 2.8 bn, 3.5%; Italy: USD 2.4 bn, 3.0%; Brazil: USD 2.4 bn, 3.0%; Canada: USD 2.0 bn, 2.5%; India: USD 2.0 bn, 2.5%.United States29.0 bn 36.0%China8.1 bn 10.0%Germany4.0 bn 5.0%Japan4.0 bn 5.0%France3.2 bn 4.0%United Kingdom2.8 bn 3.5%Italy2.4 bn 3.0%Brazil2.4 bn 3.0%Canada2.0 bn 2.5%India2.0 bn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 29.0 bn36.0%USD 57.2 bn7.0%
2ChinaUSD 8.1 bn10.0%USD 16.6 bn7.5%
3GermanyUSD 4.0 bn5.0%USD 7.6 bn6.6%
4JapanUSD 4.0 bn5.0%USD 7.0 bn5.6%
5FranceUSD 3.2 bn4.0%USD 5.9 bn6.2%
6United KingdomUSD 2.8 bn3.5%USD 5.4 bn6.7%
7ItalyUSD 2.4 bn3.0%USD 4.3 bn5.9%
8BrazilUSD 2.4 bn3.0%USD 5.1 bn7.7%
9CanadaUSD 2.0 bn2.5%USD 3.8 bn6.6%
10IndiaUSD 2.0 bn2.5%USD 5.2 bn10.0%
11SpainUSD 1.9 bn2.4%USD 3.8 bn7.0%
12MexicoUSD 1.9 bn2.4%USD 3.8 bn7.0%
13IndonesiaUSD 1.5 bn1.9%USD 3.6 bn9.1%
14TurkeyUSD 1.2 bn1.5%USD 2.9 bn9.1%
15RussiaUSD 1.0 bn1.3%USD 1.7 bn5.3%
16AustraliaUSD 902 mn1.1%USD 1.5 bn5.4%
17NetherlandsUSD 806 mn1.0%USD 1.4 bn5.4%
18BelgiumUSD 733 mn0.9%USD 1.2 bn5.4%
19SwitzerlandUSD 669 mn0.8%USD 1.1 bn5.3%
20South KoreaUSD 620 mn0.8%USD 1.0 bn5.4%
21ArgentinaUSD 572 mn0.7%USD 1.4 bn9.2%
22PolandUSD 540 mn0.7%USD 1.3 bn9.1%
23PakistanUSD 508 mn0.6%USD 1.2 bn9.2%
24ThailandUSD 475 mn0.6%USD 1.1 bn9.2%
25Saudi ArabiaUSD 451 mn0.6%USD 1.1 bn9.3%
Rest of worldUSD 6.6 bn8.2%USD 12.0 bn6.2%
Exhibit 5United States and China account for 47% of the USD 77.9 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Vaccines market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 80.6 bn. United States: +USD 28.2 bn; China: +USD 8.6 bn; Germany: +USD 3.6 bn; India: +USD 3.2 bn; Japan: +USD 2.9 bn; 20 other countries: +USD 26.0 bn; Rest of world: +USD 5.4 bn. Market value 2036: USD 158 bn.Market value 202680.6 bnUnited States+28.2 bnChina+8.6 bnGermany+3.6 bnIndia+3.2 bnJapan+2.9 bn20 other countries+26.0 bnRest of world+5.4 bnMarket value 2036158 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • GSK
  • Pfizer
  • Merck
  • Sanofi
  • Moderna
  • CSL Seqirus
  • Sinopharm

Group 2: Regional and specialist players

  • Serum Institute of India
  • Bharat Biotech
  • Sinovac
  • Takeda
  • BioNTech
  • Zhifei Biological Products
  • CanSino Biologics
  • SK bioscience
  • Butantan Institute
  • Emergent BioSolutions

Group 3: Emerging and niche players

  • Novavax
  • Valneva
  • Bavarian Nordic
  • Biological E
  • Dynavax
  • Vaxcyte
  • Walvax Biotechnology
  • Bio Farma

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the vaccines market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.

The market is divided by disease, by technology, by age, by administration, by buyer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the vaccines market?

The global vaccines market is estimated at USD 76.0 bn in 2025 and USD 80.6 bn in 2026.

How fast will the vaccines market grow?

It is forecast to reach USD 158 bn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 77.9 bn.

Which country is the largest market for vaccines?

United States is the largest market by revenue at USD 29.0 bn in 2026, 36.0% of the global total. The three largest countries together hold 51.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 10.0% a year from 2026 to 2036.

Which vaccines segment is largest?

In the by disease split, Childhood combination and others is the largest segment with 33.0% of 2026 revenue.

Who are the leading vaccines companies?

Global leaders include GSK, Pfizer, Merck, Sanofi.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Vaccine Cryoprotectants Vaginitis Screening Assays →

All Healthcare markets →

Request a sample